Twist Bioscience Corp income statement

In fiscal 2025, Twist Bioscience Corp reported revenue of $377m, up 20.3% on the year before, operating income of −$136m (a -36.2% margin) and net income of −$77.7m, or −$1.30 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Twist Bioscience Corp: income statement, annual
Fiscal year	2017Sept 2017	2018Sept 2018	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025	LTMJun 2026
Revenue	11	25	54	90	132	204	245	313	377	432
Cost of revenue	24	32	47	61	81	119	155	180	186	207
Gross profit	−13	−7	7	29	52	84	90	133	191	224
Research and development	19	20	36	43	69	120	107	91	80	72
Selling, general and administrative	26	43	80	103	136	213	190	218	247	290
Operating income	−58	−71	−109	−140	−153	−235	−217	−221	−136	−145
Interest expense	1	1	1	1	0	0	0	0	—	—
Income before tax	−59	−71	−107	−140	−154	−228	−203	−208	−77	−136
Income tax	0	0	0	0	−2	−10	1	1	1	1
Net income	−59	−71	−108	−140	−152	−218	−205	−209	−78	−137
Diluted EPS	−$24.49	−$25.51	−$3.92	−$3.57	−$3.15	−$4.04	−$3.60	−$3.60	−$1.30	−$2.24
Diluted shares (average)	2,422m	—	27m	39m	48m	54m	57m	58m	60m	61m
EBITDA	−53	−65	−103	−133	−143	−218	−188	−189	−111	−120

US$ millions unless shown otherwise. Fiscal quarters.

Twist Bioscience Corp: income statement, quarterly
Quarter	2024 Q4Sept 2024	2025 Q1Dec 2024	2025 Q2Mar 2025	2025 Q3Jun 2025	2025 Q4Sept 2025	2026 Q1Dec 2025	2026 Q2Mar 2026	2026 Q3Jun 2026
Revenue	85	89	93	96	99	104	111	118
Cost of revenue	46	46	47	45	48	50	54	56
Gross profit	38	43	46	51	51	54	57	62
Research and development	21	21	24	18	17	17	20	18
Selling, general and administrative	53	56	64	63	64	70	76	81
Operating income	−36	−35	−42	−30	−30	−33	−46	−36
Interest expense	0	0	0	—	—	—	—	—
Income before tax	−35	−31	−39	21	−27	−30	−44	−35
Income tax	−0	0	0	0	0	0	0	0
Net income	−35	−32	−39	20	−27	−31	−44	−35
Diluted EPS	−$0.59	−$0.53	−$0.66	$0.33	−$0.45	−$0.50	−$0.71	−$0.56
EBITDA	−29	−28	−35	−24	−24	−27	−40	−30

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CSTL vs TWST TWST vs VCYT FLGT vs TWST

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Twist Bioscience Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Twist Bioscience Corp.